Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.

Hepatology (Baltimore, Md.) - 1 Apr 2007

Inoue Kazuaki, Umehara Takuya, Ruegg Urs T, Yasui Fumihiko, Watanabe Tsunamasa, Yasuda Hiroshi, Dumont Jean-Maurice, Scalfaro Pietro, Yoshiba Makoto, Kohara Michinori

Abstract excerpt

UNLABELLED: Cyclosporin A (CsA) inhibits replication of the HCV subgenomic replicon, and this effect is believed to not be mediated by its immunosuppressive action. We found that DEBIO-025, a novel non-immunosuppressive cyclophilin inhibitor derived from CsA, inhibited HCV replication in vitro more potently than CsA. We also examined the inhibitory effect of DEBIO-025 on naive HCV genotypes 1a or 1b in vivo using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophilins
Share to Cyclosporine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppression Therapy

Share to Interferon alpha-2

Share to Replicon

Share to Serum Albumin

Share to Transplantation Chimera

Share to Viral Core Proteins

Source

Identifiers

PMID: 17393519
DOI: 10.1002/hep.21587

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.PMID 17393519Read ↗

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral ActivitySemantic proximity Read ↗

Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C InfectionSemantic proximity Read ↗

Identification of cellular and viral factors related to anti‐hepatitis C virus activity of cyclophilin inhibitorSemantic proximity Read ↗

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agentsSemantic proximity Read ↗

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.Semantic proximity Read ↗

New targets for antiviral therapy of chronic hepatitis C.Semantic proximity Read ↗

Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.Semantic proximity Read ↗

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.Semantic proximity Read ↗

Hepatitis E virus genome replication is independent of cyclophilins A and BSemantic proximity Read ↗

Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti‐hepatitis C virus strategySemantic proximity Read ↗

Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.Semantic proximity Read ↗

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.